November 25, 2020
Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Novocure’s Executive Chairman William Doyle and Chief Science Officer Dr. Uri Weinberg will participate in the 3rd Annual Evercore ISI 2020 Virtual HealthCONx Conference on December 1 through December 2, 2020. Mr. Doyle and Dr. Weinberg will take part in… Read More
learn more
November 19, 2020
Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting
Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual… Read More
learn more
November 11, 2020
Novocure Receives CE Mark for NovoTTF-100L™ System
The application of CE mark enables Novocure to commercialize the NovoTTF-100L System as a treatment for Malignant Pleural Mesothelioma in the European Union and Switzerland ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer,… Read More
learn more
November 10, 2020
Novocure Announces Agenda for Virtual Research and Development Day
Event will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. Read More
learn more
November 9, 2020
Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks
Provides flexible capital structure prior to anticipated period of significant innovation and growth ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 million senior secured revolving… Read More
learn more
November 5, 2020
Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement
Initial conversion price represents a premium of approximately 50% ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the closing of its previously announced offering of $575 million aggregate principal amount of… Read More
learn more
November 2, 2020
Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement
Initial conversion price represents a premium of approximately 50% ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the pricing of $500 million aggregate principal amount of its 0% Convertible Senior Notes due… Read More
learn more
November 2, 2020
Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced its intention to offer $500 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”). The notes will be offered in a… Read More
learn more
